Project Grant RF1NS144499
- This Project Grant award of $717,709 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to discover cellular mechanisms underlying the propagation of misfolded tau protein aggregates in human neurons, which are key drivers of cognitive decline in Alzheimer's disease (AD) and frontotemporal dementia (FTD). The research combines advanced proteomic techniques, deep learning analyses, and transcriptomic profiling using newly generated human induced pluripotent stem...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $433,125 will fund a study to investigate the relationship between microglia, neurons, and tau pathology in Alzheimer's disease. The research will utilize a novel model system of microglial co-cultures with hippocampal assembloids derived from patient-derived induced pluripotent stem cell (iPSC) lines with MAPT mutations and healthy controls. The goal is to explore how bidirectional changes...
- This federal Project Grant award of $238,410 from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders will fund a 5-year mentored research project led by Dr. Sarah Kaufman at the University of California, San Francisco. The project aims to elucidate the mechanisms underlying tau aggregation and neurotoxicity in Alzheimer's disease and frontotemporal lobar degeneration. The research...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,540,579 project grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the Regenerative Research Foundation in Rensselaer, NY. The 2-year grant, with a start date of June 1, 2025, will fund the development and validation of a novel, cellularly complex 3D human cell model of frontotemporal dementia (FTD) due to MAPT gene mutations. The goal is to create a model...
- This Project Grant award of $1,257,528 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Novoron Bioscience Inc. is focused on developing a platform to evaluate novel therapies designed to inhibit the propagation and aggregation of pathological tau protein, which is a key driver of Alzheimer's disease and other tauopathies. The platform will leverage human induced pluripotent stem cell (hiPSC)-derived neural organoids, including both wild-type and LRP1 knockout organoids, to...
- The National Institute on Aging awarded a $1,931,965 Project Grant (CFDA 93.866 - Aging Research) to the Regenerative Research Foundation, a non-profit organization in Albany, New York. The purpose of this federal grant is to develop and validate a novel human induced pluripotent stem cell (iPSC) model that incorporates cerebral cortical neurons, glia, vascular endothelial cells, and microglia to study cerebrovascular interactions in Alzheimer's disease-related dementias (ADRD). The R61 phase of...
- This $816,661 Project Grant award, issued on June 1, 2025 by the National Institute on Aging (CFDA 93.866 Aging Research program), supports comprehensive research aimed at elucidating the molecular mechanisms underlying tauopathies such as Alzheimer's disease and frontotemporal dementia. The project, titled "Aberrant Proteomes in Tauopathy: Revealing Functional Consequences via Multimodal Proteomics", combines expertise in mass spectrometry-based proteomics and functional genomics to...
- This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Regents of the University of California, San Francisco (UCSF) on August 1, 2025 for $1,180,687. The purpose of this 8-year project is to investigate how neural stem cell niches transition from embryonic to postnatal stages in the human forebrain, with a focus on characterizing the different neural...
- This $2,683,965 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports the development and optimization of an "all-human cellular system" or "brain-chip" to study the cellular mechanisms underlying vulnerability to Alzheimer's disease (AD). The grant enables researchers at Brigham & Women's Hospital Inc. to leverage...
This $3,109,857 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development and validation of a human induced pluripotent stem cell (iPSC)-derived hippocampal assembloid model to study the interaction between interneurons, tau toxicity, and circuit-related neuronal dysfunction associated with genetic forms of dementia. The research aims to generate iPSC-derived hippocampal assembloids expressing mutations in the microtubule-associated protein tau (MAPT) that cause frontotemporal dementia, in order to investigate how these mutations impact interneurons and neural circuit function. This model, once validated, will provide opportunities to further explore the mechanistic links between interneuron biology, tau pathology, and cognitive decline in genetically-encoded dementias. The award period runs from August 1, 2025 to July 31, 2029 and is being led by researchers at the University of California, Los Angeles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $3.1m | 8/4/25 |